Hikma Pharmaceuticals (FRA:H5P) Total Liabilities : €2,685 Mil (As of Dec. 2024)

View and export this data going back to . Start your Free Trial

What is Hikma Pharmaceuticals Total Liabilities?

Hikma Pharmaceuticals's Total Liabilities for the quarter that ended in Dec. 2024 was €2,685 Mil.

Hikma Pharmaceuticals's quarterly Total Liabilities increased from Dec. 2023 (€2,265.91 Mil) to Jun. 2024 (€2,366.16 Mil) and increased from Jun. 2024 (€2,366.16 Mil) to Dec. 2024 (€2,685.46 Mil).

Hikma Pharmaceuticals's annual Total Liabilities increased from Dec. 2022 (€2,192.91 Mil) to Dec. 2023 (€2,265.91 Mil) and increased from Dec. 2023 (€2,265.91 Mil) to Dec. 2024 (€2,685.46 Mil).

Hikma Pharmaceuticals Total Liabilities Historical Data

The historical data trend for Hikma Pharmaceuticals's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Hikma Pharmaceuticals Total Liabilities Chart

Hikma Pharmaceuticals Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Total Liabilities

Get a 7-Day Free Trial

1,633.31

1,685.93

2,192.91

2,265.91

2,685.46

Hikma Pharmaceuticals Semi-Annual Data
	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24
Total Liabilities	Get a 7-Day Free Trial															2,192.91	2,230.89	2,265.91	2,366.16	2,685.46

Hikma Pharmaceuticals Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Hikma Pharmaceuticals's Total Liabilities for the fiscal year that ended in Dec. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	1888.99	+	(623.615	+	172.855
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit	+	NonCurrent Deferred Income Tax)
	+	0	+	0	+	0)
	=	2,685

Total Liabilities	=	Total Assets (A: Dec. 2024 )	-	Total Equity (A: Dec. 2024 )
	=	4902.015	-	2216.555
	=	2,685

Hikma Pharmaceuticals's Total Liabilities for the quarter that ended in Dec. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	1888.99	+	(623.615	+	172.855
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit	+	NonCurrent Deferred Income Tax)
	+	0	+	0	+	0)
	=	2,685

Total Liabilities	=	Total Assets (Q: Dec. 2024 )	-	Total Equity (Q: Dec. 2024 )
	=	4902.015	-	2216.555
	=	2,685

Hikma Pharmaceuticals Total Liabilities Related Terms

Thank you for viewing the detailed overview of Hikma Pharmaceuticals's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Hikma Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Hikma Pharmaceuticals PLC (FRA:H5P) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

HKMPY:USA HKMPF:USA HIKl:UK HIK:UK

Address

1 New Burlington Place, London, GBR, W1S 2HR

Website

https://www.hikma.com

Hikma Pharmaceuticals PLC is engaged in developing, manufacturing, and marketing a broad range of generic, branded and non-branded, in-licensed pharmaceutical products. The firm operates in three segments: injectables, generics, and branded. The majority of the revenue for the company is generated from its injectables segment under which it supplies hospitals across markets with generic injectable products, supported by its manufacturing facilities. Geographically, North America is the company's key revenue generating market followed by Middle East and North Africa, United Kingdom, Europe and the rest of the world.

Hikma Pharmaceuticals Headlines

No Headlines